Table 1 Clinicopathological and survival characteristics of the dataset of 250 serous ovarian tumors
From: A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors
Characteristics | HGSC, n (%) n = 114 | LGSC, n (%) n = 97 | mSBT, n (%) n = 39 |
|---|---|---|---|
Age at diagnosis (years) | |||
Median (range) | 60 (36–81) | 55 (19–83) | 51 (25–85) |
Mean ± SD | 60 ± 10.1 | 52 ± 14.6 | 51 ± 14.5 |
Follow up (months) | |||
Median (range) | 38 (0–251) | 45 (0–320) | 56 (5–189) |
Mean ± SD | 43 ± 33.1 | 56 ± 55.9 | 53 ± 43.3 |
FIGO | |||
I | 9 (8%) | 14 (14%) | 11 (28%) |
II | 7 (6%) | 5 (5%) | 0 (0%) |
III | 68 (60%) | 51 (53%) | 16 (41%) |
IV | 28 (24%) | 2 (2%) | 0 (0%) |
NA | 2 (2%) | 25 (26%) | 12 (31%) |
T-stage | |||
T1 | 13 (11%) | 14 (14%) | 11 (28%) |
T2 | 13 (11%) | 5 (5%) | 0 (0%) |
T3 | 85 (75%) | 52 (54%) | 16 (41%) |
Tx/NA | 3 (3%) | 26 (27%) | 12 (31%) |
N-stage | |||
N0 | 29 (25%) | 18 (18%) | 10 (26%) |
N1 | 44 (39%) | 20 (21%) | 2 (5%) |
Nx/NA | 41 (36%) | 59 (61%) | 27 (69%) |
M-stage | |||
M0 | 69 (61%) | 68 (70%) | 25 (64%) |
M1 | 28 (24%) | 2 (2%) | 0 (0%) |
Mx/NA | 17 (15%) | 27 (28%) | 14 (36%) |
Survival status | |||
NED | 28 (24%) | 36 (37%) | 17 (44%) |
AWD | 61 (54%) | 25 (26%) | 5 (13%) |
DOD | 24 (21%) | 12 (12%) | 2 (5%) |
DOC | 0 (0%) | 8 (8%) | 1 (3%) |
NA | 1 (1%) | 16 (16%) | 14 (36%) |
Local recurrence | |||
No | 53 (47%) | 54 (56%) | 20 (51%) |
Yes | 57 (50%) | 24 (25%) | 5 (13%) |
NA | 4 (3%) | 19 (20%) | 14 (36%) |
Distant metastasis | |||
No | 71 (62%) | 62 (64%) | 25 (64%) |
Yes | 39 (34%) | 16 (16%) | 0 (0%) |
NA | 4 (4%) | 19 (20%) | 14 (36%) |